Telehealth Boss Turned Adderall Into Gold

July 13, 2026

The prosecution of Done Global’s founder for turning a telehealth ADHD service into an industrial-scale Adderall pipeline marks a defining case in how traditional drug laws now reach into the architecture of digital health platforms.

Key Points

Done Global’s founder and CEO, Ruthia He, was sentenced to six years in federal prison and fined $1 million for a scheme that unlawfully distributed over 37 million Adderall pills via telehealth.
A federal jury convicted He and clinical president David Brody of conspiracy to distribute controlled substances, multiple distribution counts, health care fraud, and, in He’s case, conspiracy to obstruct justice.
The company’s technology, compensation model, and clinical protocols were engineered to drive high-volume stimulant prescribing and to defraud insurers of more than $12 million.
The case sits squarely within a broader post‑pandemic crackdown on “telehealth pill mills” that exploited emergency prescribing flexibilities to move controlled substances at scale.

From ADHD Telehealth Platform to Industrial Adderall Pipeline

Done Global began as a digital health startup promising convenient ADHD evaluations and medication access through telehealth. What the evidence showed at trial, however, was not a marginal compliance failure but a business model built around high‑velocity Adderall distribution and revenue maximization. According to the Justice Department, He orchestrated a scheme that used the company’s technology platform, compensation structure, and clinical protocols to unlawfully distribute more than 37 million Adderall pills, positioning Done as a ready source of stimulants for over 100,000 people across the United States.

He was not merely a passive executive atop a sprawling operation. Prosecutors described her as the architect of a system designed to make stimulant prescribing frictionless: streamlined online intake, brief or nonexistent clinical encounters, and standardized decision pathways that effectively defaulted to approval. The company charged monthly subscription fees for ongoing access, turning what should have been individualized controlled‑substance prescribing into a recurring revenue product.

The Convictions: Drug Distribution, Fraud, and Obstruction

In November 2025, after a multi‑week trial in federal court in San Francisco, a jury convicted He and Done’s clinical president, psychiatrist David Brody, on core narcotics and fraud charges. Both were found guilty of one count of conspiracy to distribute controlled substances, four counts of distribution of controlled substances, and one count of conspiracy to commit health care fraud. He was additionally convicted of conspiracy to obstruct justice, reflecting her role not only in building the scheme but in attempting to impede the investigation once federal scrutiny intensified.

The obstruction count is significant even though the public record does not yet detail the specific acts that supported it. In complex health‑care prosecutions, obstruction often involves coaching witnesses, destroying or altering records, or manipulating internal systems to frustrate audits. What matters for understanding this case is that jurors concluded, beyond a reasonable doubt, that He crossed the line from aggressive defense of her company into criminal interference with the justice process.

Clinical Protocols as a Vector for Illegal Prescribing

The mechanism of harm in the Done scheme was not a single rogue prescriber but a systemic design that encouraged what regulators sometimes call “assembly‑line medicine.” The New York Times reported that clinicians affiliated with Done issued Adderall prescriptions at intervals as short as 30 seconds, an astonishing cadence for a Schedule II controlled substance that, by law and clinical standards, requires careful diagnostic evaluation and monitoring. That kind of tempo does not emerge by accident; it reflects protocols, incentives, and technology that treat prescribing as a high‑throughput workflow rather than a deliberative clinical act.

Brody, as clinical president, sat at the center of that design. Evidence presented in sentencing materials and reporting shows that he personally prescribed 394,324 stimulant pills to patients he never assessed directly. From a medical‑ethics standpoint, this volume and lack of true patient contact are glaring red flags. From a legal standpoint, they formed part of the government’s proof that the company was not providing legitimate telehealth care but facilitating unlawful drug distribution at scale.

Deceptive Advertising and the $90–$100 Million Business Model

The Done case was not only about pills; it was also about money. Federal agencies, including IRS Criminal Investigation, have described the scheme as a $90–$100 million operation built on subscription revenues and fraudulent insurance reimbursement. Done submitted false and misleading claims to insurers, yielding more than $12 million in improper payments, according to the sentencing press release. Those claims turned clinically dubious prescriptions into direct financial harm to public and private payers.

To feed that revenue engine, the company invested heavily in marketing. IRS Criminal Investigation reported that He and Done spent more than $40 million on social media advertising designed to convince Americans struggling with pandemic‑era disruption that they were suffering from ADHD and needed stimulant treatment. The messaging tapped into real anxieties—difficulty concentrating while working from home, children’s disrupted schooling—and reframed them as symptoms of a diagnosable disorder best addressed by joining Done’s platform. From a regulatory perspective, this kind of advertising magnifies concern: it simultaneously expands the pool of potential “patients” and lowers the threshold for initiating controlled‑substance use.

Sentencing: Six Years for the Founder, Two Years for the Clinician

Against that backdrop, U.S. District Judge Charles Breyer sentenced He to 72 months in prison and imposed a $1 million fine. While federal statutes allowed for maximum penalties of 20 years on the drug counts, sentencing guidelines and specific case factors typically drive much lower terms. In this instance, the judge appears to have weighed the scope of the scheme, its financial and public‑health impact, He’s leadership role, and her obstructive conduct, arriving at a six‑year term that situates the case toward the serious end of health‑care fraud but short of the longest drug‑distribution sentences reserved for more traditional trafficking operations.

Brody received a separate sentence of 24 months, reflecting both his clinical authority and the prosecution’s framing of his role as distinct from He’s entrepreneurial and operational leadership. That disparity underscores a key feature of the case: federal authorities treated the corporation’s design and the executive team’s decisions as central to the illegality, not merely the conduct of individual prescribers following orders.

A Test Case in Telehealth Enforcement After COVID‑19

Done’s rise and fall occurred in the specific regulatory climate of the COVID‑19 pandemic. Emergency measures relaxed longstanding requirements—such as in‑person visits under the Ryan Haight Act—for prescribing certain controlled substances via telemedicine. Those flexibilities were intended to maintain continuity of care when clinics were closed, not to license high‑volume stimulant operations. Yet they created openings that bad actors could exploit, and Done became one of the most prominent examples.

The Justice Department has explicitly tied this case to a broader enforcement campaign against telehealth fraud and “pill mills” that used remote prescribing rules to move controlled substances and bill insurers aggressively. Parallel analyses from agencies and researchers highlight common features in such schemes: unbelievable visit volumes per clinician, minimal or no documented patient contact, geographic mismatches between providers and patients, and patterns of billing at the highest codes for telehealth services. Done’s practices align neatly with those red flags, which is part of why its prosecution has been cited as a “first‑ever” federal drug distribution case centered on a telehealth platform.

Psychiatrist David Brody gets two years prison for Adderall distribution scheme

Former Done Global Clinical President Dr. David Brody has been sentenced to two years in federal prison and fined $1 million for his role in a multimillion-dollar telehealth scheme that illegally…

— PsychCrime (@psychcrime) July 9, 2026

Where the Public Record Is Strong—and Where It Is Thin

From an evidentiary standpoint, the backbone of this story is unusually robust. Multiple federal agencies—the Justice Department’s Criminal Division, the U.S. Attorney’s Office, HHS’s Office of Inspector General, DEA, and IRS Criminal Investigation—have issued consistent accounts of the same underlying facts: the conviction on specific counts, the scale of pills distributed, the revenue and fraud totals, and the sentences imposed. Major media outlets, including the Wall Street Journal and the New York Times, have reported the case using those records without significant contradiction.

At the same time, the publicly available materials leave gaps that matter for a fine‑grained understanding of harm and responsibility. The indictment, trial exhibits, and sentencing memoranda are not widely accessible, which means outside observers cannot yet scrutinize the precise data behind the 37‑ to 40‑million‑pill counts or the $90–$100 million revenue figures. The record, as reported, includes remarkably high prescribing volumes and references to patient overdoses and addiction, but it does not feature detailed, named victim narratives. Nor does it spell out the specific steps He took that resulted in the obstruction conviction. Those are questions more suited to court‑document analysis than to press releases, and they will likely be clarified as legal analysts work through the case files over time.

Implications for Digital Health and Controlled Substances

For the wider telehealth industry, the Done case is a warning shot with practical consequences. First, it demonstrates that law enforcement is prepared to treat a telehealth platform as a drug‑distribution enterprise when its design and marketing push clinicians toward rote prescribing of controlled substances. The legal focus is not on the novelty of the technology but on the old‑fashioned questions: Were prescriptions medically necessary? Were claims truthful? Were executive decisions oriented toward patient care or profit?

Second, the case highlights the regulatory sensitivity around stimulants, particularly Adderall, in a culture where ADHD diagnoses and treatment have expanded. When a company spends tens of millions of dollars persuading people they have ADHD, then offers almost frictionless access to Schedule II medications, regulators will ask whether it has effectively created demand for drugs rather than responded to existing medical need. The answer in Done’s case was clear enough to secure unanimous guilty verdicts.

Finally, the prosecution illustrates how corporate design choices—subscription models, prescriber compensation systems, algorithmic protocols—can themselves be treated as instruments of illegal drug distribution. That framing will continue to shape how founders, investors, and clinicians think about building digital health businesses around medications with abuse potential. Telehealth is now a permanent part of the care landscape, but the era when its controlled‑substance workflows could evolve without close regulatory attention is over.